To investigate the effects of garlicin capsule on immune function in patients with breast cancer undergoing chemotherapy.

Form April 2018 to October 2018, 62 patients with breast cancer were treated by operation in Tangshan People′s Hospital and pathologically diagnosed as breast cancer.Random number table method was used to divide the patients into treatment group and control group, with 31 cases in each group.The treatment group was given garlicin capsule combined with EC regimen( the first day(epirubicin hydrochloride injection 90 mg/m² + cyclophosphamide 90 mg/m²) , 21 days for one cycle, four consecutive cycles), while the control group was given EC regimen alone for 4 courses.The occurrence of adverse reactions was recorded.T lymphocyte subsets were detected before and after treatment to evaluate the immune function of the body.

There was no significant difference in the number of adverse reactions between the two groups after treatment (Seventy in the treatment group and 69 in the control group) (P>0.05). The levels of CD3⁺ , CD4⁺ , CD8⁺ and CD4⁺ /CD8⁺ were (53.76±4.29)%, (40.19±3.71)%, (28.61±2.75)% and (1.41±0.16) in the treatment group before chemotherapy, respectively.While after chemotherapy were (52.41±4.44)%, (39.49±4.06)%, (28.70±2.76)% and (1.35±0.94), respectively.The levels of CD3⁺ , CD4⁺ , CD8⁺ and CD4⁺ /CD8⁺ were (54.35±4.09)%, (40.70±4.09)%, (27.62±3.60)% and (1.49±0.24) in the control group before chemotherapy, respectively.While after chemotherapy were (44.27±6.67)%, (35.39±4.96)%, (30.48±3.43)% and (1.17±0.20). After treatment, the levels of CD3⁺ , CD4⁺ , CD4⁺ / CD8⁺ decreased and CD8⁺ increased, but there had no significant difference(P>0.05). After treatment, CD3⁺ (decreased from(54.35±4.09)% to (44.27±6.67)%), CD4⁺ (decreased from (40.70±4.09)% to (35.39±4.96)%), CD4⁺ /CD8⁺ ((decreased from (1.49±0.24) to (1.17±0.20)), the difference was statistically significant(t value was 7.17, 4.60, 5.71, -3.02, P value was 0.000, 0.000, 0.002, 0.000). Compared with control group, the levels of CD3⁺ 、CD4⁺ 、CD4⁺ / CD8⁺ in treatment group increased and CD8⁺ decreased significantly (all P<0.01).

Garlicin capsule can improve the depression of immune function caused by chemotherapy.

Breast cancer; Garlicin capsule; Chemotherapy; Immune function